齐拉西酮治疗精神分裂症阴性症状对照研究  

A comparative study of ziprasidone and sulpiride in the treatment for schizophrenia with predominantly negative symptoms

作　　者：杨春强[1] 李洪英[1] 王学文[1] 李宝霞[1] 杨程皓[1] 

机构地区：[1]天津市安定医院,300074

出　　处：《临床精神医学杂志》2009年第6期409-410,共2页Journal of Clinical Psychiatry

摘　　要：目的:探讨齐拉西酮与舒必利治疗以阴性症状为主的精神分裂症患者的疗效及安全性。方法:将60例以阴性症状为主的精神分裂症患者随机分为齐拉西酮组与舒必利组,每组30例,分别给予齐拉西酮和舒必利治疗,疗程8周。以简明精神病评定量表(BPRS)和阴性症状评定量表(SANS)及治疗中出现的症状量表(TESS)评定疗效及不良反应。结果:齐拉西酮与舒必利对阴性症状均有较好疗效,但齐拉西酮对意志缺乏及注意障碍的改善更明显,且不良反应少。结论:齐拉西酮是治疗以阴性症状为主的精神分裂症理想药物。Objective： To explore the efficacy and safety of ziprasidone and sulpiride in the treatment for schizophrenia with predominantly negative symptoms. Method：60 schizophrenics with predominantly negative symptoms were randomly divided into ziprasidone （n = 30 ） and sulpiride（ n = 30 ） group for 8 weeks. The efficaey and side effects were assessed with BPRS, SANS and TESS respectively. Results：Both groups showed significant efficacy in the treatment of negative symptoms and the total efficacy was no significant difference between the two groups （P 〉 0.05 ） , but ziprasidone was more effective in improving abulia and attention disorder, the side effects of ziprasidone were few and slight. Conclusion ： Ziprasidone is an very effective and safe antipsychoties in the treatment for schizophrenia with predominantly negative symptoms.

关 键 词：精神分裂症 阴性症状 齐拉西酮 舒必利 

分 类 号：R749.3[医药卫生—神经病学与精神病学]